Novel anti-prion compounds screening in prion-infected cell culture model combined with surface plasmon resonance analysis

RT:

Room Temperature

FBS:

Fetal Bovine Serum

DMEM:

Dulbecco’s Modified Eagle Medium

PK:

Proteinase K

2D-SSS:

2D-Substructure search

MC:

Medical Chaperon N, N’-([cyclohexylmethylene]di-4,1-phenylene)bis(2-[1-pyrrolidinyl]acetamide

TSEs:

Transmissible spongiform encephalopathies

rt:

Retention time

1. Colini, B. A. et al. Innovative non-PrP-targeted drug strategy designed to enhance prion clearance. J. Med. Chem. 65, 8998–9010. https://doi.org/10.1021/acs.jmedchem.2c00205 (2022).

   Google Scholar 

2. How Prions Came to Be. A Brief History – Infectious Disease: Superbugs, Science, & Society. Archived from the original on 2021-09-17. Retrieved 2021-09-17.

3. Kuwata, K. et al. Hot spots in prion protein for pathogenic conversion. Proc. Natl. Acad. Sci. U S A. 104, 11921–11926. https://doi.org/10.1073/pnas.0702671104 (2007).

   Google Scholar 

4. Spagnolli, G. et al. Pharmacological inactivation of the prion protein by targeting a folding intermediate. Commun. Biol. 4, 62. https://doi.org/10.1038/s42003-020-01585-x (2021).

   Google Scholar 

5. Massignan, T. et al. A Small-Molecule inhibitor of prion replication and mutant prion protein toxicity. Chem. Med. Chem. 12, 1286–1292. https://doi.org/10.1002/cmdc.201700302 (2017).

   Google Scholar 

6. Altieri, A. et al. Generation, optimization and characterization of novel anti-prion compounds. Bioorg. Med. Chem. 28, 115717. https://doi.org/10.1016/j.bmc.2020.115717 (2020).

   Google Scholar 

7. Atarashi, R. et al. Prion-strain-dependent differences in conversion of mutant prion proteins in cell culture. J. Virol. 80, 7854–7862. https://doi.org/10.1128/JVI.00424-06 (2006).

   Google Scholar 

8. Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175–178. https://doi.org/10.1038/nm.2294 (2011).

   Google Scholar 

9. Ishibashi, D. et al. Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice. Vaccine 29, 9321–9328. https://doi.org/10.1016/j.vaccine.2011.10.017 (2011).

   Google Scholar 

10. Homma, T. et al. Oligoadenylate synthetase 1a suppresses prion infection through binding to cellular prion protein. Brain https://doi.org/10.1093/brain/awaf193 (2025).

    Google Scholar 

11. Ishibashi, D. et al. Novel compounds identified by Structure-Based prion disease drug discovery using In Silico screening delay the progression of an illness in prion-Infected mice. Neurotherapeutics 17, 1836–1849. https://doi.org/10.1007/s13311-020-00903-9 (2020).

    Google Scholar 

12. Ishibashi, D. et al. Structure-based drug discovery for prion disease using a novel binding simulation. EBioMedicine 9, 238–249. https://doi.org/10.1016/j.ebiom.2016.06.010 (2016).

    Google Scholar 

13. Ishibashi, D. et al. Strain-dependent effect of macroautophagy on abnormally folded prion protein degradation in infected neuronal cells. PloS One. 10, e0137958. https://doi.org/10.1371/journal.pone.0137958 (2015).

    Google Scholar 

14. Shiraishi, S. et al. Taste-Masking effect of chlorogenic acid (CGA) on bitter drugs evaluated by taste sensor and surface plasmon resonance on the basis of CGA-Drug interactions. Chem. Pharm. Bull. (Tokyo). 65, 127–133. https://doi.org/10.1248/cpb.c16-00621 (2017).

    Google Scholar 

15. Shiraishi, S. et al. Chem. Pharm. Bull. 65, 127–133. https://doi.org/10.1248/cpb.c16-00621 (2017).

    Google Scholar 

16. Yamaguchi, K. et al. A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques. Nat. Biomed. Eng. 3, 206–219. https://doi.org/10.1038/s41551-019-0349-8 (2019).

    Google Scholar 

17. Kyu Hwan Shim. Niti Sharma & Seong Soo A An. Prion therapeutics: lessons from the past. Prion 16, 265–294. https://doi.org/10.1080/19336896.2022.2153551 (2022).

    Google Scholar 

18. Sigurdson, C. J., Bartz, J. C. & Glatzel, M. Cellular and molecular mechanisms of prion disease. Annu. Rev. Pathol. 14, 497–516. https://doi.org/10.1146/annurev-pathmechdis-012418-013109 (2019).

    Google Scholar 

19. Fornari Sveva, S., Amelie, J., Mathias, G. A. & Kuhl Ellen. Prion-like spreading of alzheimer’s disease within the brain’s connectome. J R Soc Interface. 16, 20190356. https://doi.org/10.1098/rsif.2019.0356 (2019).

    Google Scholar 

20. Kellett, K. A. & Hooper, N. M. Prion protein and alzheimer disease. Prion 3, 190–194. https://doi.org/10.4161/pri.3.4.9980 (2009).

    Google Scholar 

21. Zhou, J. & Liu, B. Alzheimer’s disease and prion protein. Intractable Rare Dis. Res. 2, 35–44. https://doi.org/10.5582/irdr.2013.v2.2.35 (2013).

    Google Scholar 

Download references

Authors and Affiliations

1. Department of Drug Delivery, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

   Mai Hazekawa

2. Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

   Mai Hazekawa & Daisuke Ishibashi

3. Chemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia

   Andrea Altieri, Evgeniy A. Spiridonov, Nikolai A. Dmitriev, Evgeny R. Lukyanenko & Alexander V. Kurkin

4. EDASA Scientific srls, Via Stingi 37, San Salvo (CH), 66050, Italy

   Andrea Altieri

5. Dulbecco Telethon Laboratory of Prions & Amyloids, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, Trento, 38123, Italy

   Emiliano Biasini

Contributions

M.H., D.I., A.A., A.V.K. and E.B. conceptualized in this project. M.H. and D.I performed biological experiment (cell culture, immune blotting, SPR analysis). E.A.S., N.A.D. and E.R.L. performed chemical experiment (Synthesis of tested compounds, physical property evaluation); M.H. and A.A. were writing and editing of the draft. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Mai Hazekawa.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions